For informational purposes only — not investment advice

← Back to signals

DSGN

Design Therapeutics, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
16.2d↓-4.6%
as of 2026-10-30 · shares short vs 2026-09-30

Fund 13D/13G Filings (4)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Point72SC 13G/A−831K3.8%
-26.4% vs SPY
-28.7% abs
2026-08-14↗
Point72SC 13G+475K5.1%
+38.7% vs SPY
+43.5% abs
2026-06-09↗
Point72SC 13G/A—4.4%
-5.4% vs SPY
+0.1% abs
2026-05-15↗
Point72SC 13G/A—9.4%—2026-02-17↗

Tracked Funds Holding (1)

FundManagerShares HeldPosition Value
Point72Steve Cohen2.3M$29M

Quarter-end 13F positions for the tracked funds holding this stock.